In this study we evaluate the lesion detection efficacy of <sup>18</sup>F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value.
<b>Conclusion:</b><sup>18</sup>F-DCFPyL-PET/CT imaging offers high detection rates in biochemically recurrent prostate cancer patients; and is positive in about 50% of patients with PSA <0.5 ng/mL, which could substantially impact clinical management.
<b>Purpose:</b> STAND, a randomized, phase II, open-label trial (NCT01431391), assessed sequencing of sipuleucel-T (an autologous cellular immunotherapy) with androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC) patients at high risk for metastasis.<b>Experimental Design:</b> Men with BRPC following prostatectomy and/or radiotherapy, a PSA doubling time ≤12 months, and no metastasis were enrolled.
The findings suggest that a fully powered study of this combination is feasible in men with biochemically recurrent prostate cancer and a moderate PSA rise rate.Prostate 77:765-775, 2017.